Literature DB >> 23444010

An ATP2B4 polymorphism protects against malaria in pregnancy.

George Bedu-Addo1, Stefanie Meese, Frank P Mockenhaupt.   

Abstract

Polymorphisms of ATP2B4 encoding an ubiquitous Ca(2+) pump protect against severe childhood malaria. We assessed the influence of a main polymorphism (rs10900585) on malaria among 834 delivering Ghanaian women. In homozygous primiparae, the odds of placental Plasmodium falciparum infection were reduced by 64%. No influence of the polymorphism on parasite density, low birth weight, or preterm delivery was discernible. However, malarial anemia was greatly reduced in primiparous carriers of the variant allele, paralleling the reduced impact of malaria on hemoglobin levels in this group. A common ATP2B4 polymorphism protects against malaria in pregnancy and related maternal anemia, suggesting ATP2B4 variant associated protection not to be limited to severe childhood malaria.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23444010     DOI: 10.1093/infdis/jit070

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Placenta-on-a-chip: a novel platform to study the biology of the human placenta.

Authors:  Ji Soo Lee; Roberto Romero; Yu Mi Han; Hee Chan Kim; Chong Jai Kim; Joon-Seok Hong; Dongeun Huh
Journal:  J Matern Fetal Neonatal Med       Date:  2015-06-15

Review 2.  The role of the red blood cell in host defence against falciparum malaria: an expanding repertoire of evolutionary alterations.

Authors:  Morgan M Goheen; Susana Campino; Carla Cerami
Journal:  Br J Haematol       Date:  2017-08-23       Impact factor: 6.998

3.  Matrix metalloproteinase-9 polymorphism 1562 C > T (rs3918242) associated with protection against placental malaria.

Authors:  Thittayil Suresh Apoorv; Phanithi Prakash Babu; Stefanie Meese; Prabhanjan P Gai; George Bedu-Addo; Frank P Mockenhaupt
Journal:  Am J Trop Med Hyg       Date:  2015-05-26       Impact factor: 2.345

4.  USP38, FREM3, SDC1, DDC, and LOC727982 Gene Polymorphisms and Differential Susceptibility to Severe Malaria in Tanzania.

Authors:  Alphaxard Manjurano; Nuno Sepúlveda; Behzad Nadjm; George Mtove; Hannah Wangai; Caroline Maxwell; Raimos Olomi; Hugh Reyburn; Christopher J Drakeley; Eleanor M Riley; Taane G Clark
Journal:  J Infect Dis       Date:  2015-03-24       Impact factor: 5.226

5.  Genetic signatures of gene flow and malaria-driven natural selection in sub-Saharan populations of the "endemic Burkitt Lymphoma belt".

Authors:  Mateus H Gouveia; Andrew W Bergen; Victor Borda; Kelly Nunes; Thiago P Leal; Martin D Ogwang; Edward D Yeboah; James E Mensah; Tobias Kinyera; Isaac Otim; Hadijah Nabalende; Ismail D Legason; Sununguko Wata Mpoloka; Gaonyadiwe George Mokone; Patrick Kerchan; Kishor Bhatia; Steven J Reynolds; Richard B Birtwum; Andrew A Adjei; Yao Tettey; Evelyn Tay; Robert Hoover; Ruth M Pfeiffer; Robert J Biggar; James J Goedert; Ludmila Prokunina-Olsson; Michael Dean; Meredith Yeager; M Fernanda Lima-Costa; Ann W Hsing; Sarah A Tishkoff; Stephen J Chanock; Eduardo Tarazona-Santos; Sam M Mbulaiteye
Journal:  PLoS Genet       Date:  2019-03-08       Impact factor: 5.917

Review 6.  Genome-wide association studies of severe P. falciparum malaria susceptibility: progress, pitfalls and prospects.

Authors:  Delesa Damena; Awany Denis; Lemu Golassa; Emile R Chimusa
Journal:  BMC Med Genomics       Date:  2019-08-14       Impact factor: 3.063

7.  Treatment with specific and pan-plasma membrane calcium ATPase (PMCA) inhibitors reduces malaria parasite growth in vitro and in vivo.

Authors:  Puji B S Asih; Josephine E Siregar; Farahana K Dewayanti; Normalita E Pravitasari; Ismail E Rozi; Andita F M Rizki; Rifqi Risandi; Kevin N Couper; Delvac Oceandy; Din Syafruddin
Journal:  Malar J       Date:  2022-06-29       Impact factor: 3.469

Review 8.  Primary Active Ca2+ Transport Systems in Health and Disease.

Authors:  M Rosario Sepúlveda; Peter Vangheluwe; Jialin Chen; Aljona Sitsel; Veronick Benoy
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-02-03       Impact factor: 10.005

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.